drug · antibody
AMJEVITA
Marketedupdated 3mo agoby $AMGN AMGEN INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval214 co-mentions · 94 sources
- drugHUMIRA188 co-mentions · 94 sources
- drugadalimumab168 co-mentions · 94 sources
- drugYUSIMRY81 co-mentions · 81 sources
- drugABRILADA81 co-mentions · 81 sources
- company$ABBVAbbVie Inc.61 co-mentions · 61 sources
- company$AMGNAMGEN INC26 co-mentions · 13 sources
- drugCYLTEZO24 co-mentions · 12 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.
targets
Tumor necrosis factor
all catalysts(13)
approval · 13
Sep 23, 2016
approval
$AMGN414.30-0.70%
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Mar 15, 2018
approval
$AMGN414.30-0.70%
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Jun 13, 2019
approval
$AMGN414.30-0.70%
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Jul 28, 2022
approval
$AMGN414.30-0.70%
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Mar 22, 2023
approval
$AMGN414.30-0.70%
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Apr 6, 2023
approval
$AMGN414.30-0.70%
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Jul 12, 2023
approval
$AMGN414.30-0.70%
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Aug 14, 2023
approval
$AMGN414.30-0.70%
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Aug 20, 2024
approval
$AMGN414.30-0.70%
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Apr 7, 2025
approval
$AMGN414.30-0.70%
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
May 20, 2025
approval
$AMGN414.30-0.70%
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Sep 17, 2025
approval
$AMGN414.30-0.70%
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
Oct 16, 2025
approval
$AMGN414.30-0.70%
AMJEVITA (ADALIMUMAB-ATTO) — FDA approval
AMJEVITA
→
News(5)
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialMoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.fiercebiotech · 2d ago
- AbbVie shares pressured as Q2 I&I beat falls below investor expectationsAbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.biospace · 11d ago
- cAMPfield lands $180M to build gut disease drugThe biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.biopharma_dive · 1mo ago
- Biogen adds more immune drugs in $1B buyout of secretive startup RayTheraThe companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues.biopharma_dive · 1mo ago
- Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.stat · 3mo ago
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that